Deitelzweig S, Neuman WR, Lingohr-Smith M, Menges B, Lin J. US emergency department visits for outpatient adverse drug events, 2013–2014. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. Treuven health analytics, data from the marketscan commercial (COM), Medicare Supplemental (MDCR), Medicaid (MDCD), 12 months ending Dec ( 2016). First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban ( 2019).
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. Connolly SJ, Crowther M, Eikelboom JW et al. Idarucizumab for dabigatran reversal – full cohort analysis. Pollack CV Jr, Reilly PA, van Ryn J et al. Summary Basis of Decision – Praxbind – Health Canada: Government of Canada ( 2019). US FDA: Department of Health and Human Services. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. warfarin: results from the ROCKET AF trial. Management of major bleeding events in patients treated with rivaroxaban vs. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W.
Rivaroxaban with or without aspirin in stable cardiovascular disease. Eikelboom JW, Connolly SJ, Bosch J et al.
Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJ et al. Oral rivaroxaban for symptomatic venous thromboembolism. Investigators E, Bauersachs R, Berkowitz SD et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Papers of special note have been highlighted as:
0 kommentar(er)
